

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market is Expected to Grow at a CAGR of 5.29% from 2021 to 2028

The global idiopathic thrombocytopenic purpura (ITP) therapeutics market is expected to reach USD 840.68 million by 2028, at a CAGR of 5.29% from 2021 to 2028.

NEWARK, UNITED STATES, NEW JERSEY, October 28, 2021 /EINPresswire.com/ -- As per the report published by The Brainy Insights, the [global idiopathic thrombocytopenic purpura \(ITP\) therapeutics market](#) is expected to grow from USD 554.61 million in 2020 to USD 840.68 million by 2028, at a CAGR of 5.29% during the forecast period 2021-2028. The North America region emerged as the largest market for the idiopathic thrombocytopenic purpura (ITP) therapeutics market and valued at USD 228.50 million in 2020. This is because North America is growing tremendously in terms of the healthcare industry. Rising occurrence of diseases coupled with the presence of high treatment rates, and favourable government initiatives, propelling the growth of the market in the North America region. On the other side, the Asia Pacific region is anticipated to grow at a considerable growth rate in the global idiopathic thrombocytopenic purpura (ITP) therapeutics market, owing to rising healthcare expenditure in the region. Moreover, sophisticated healthcare infrastructure in the countries such as Japan and Australia, fuelling the growth of the market.

Get Free Sample Report: <https://www.thebrainyinsights.com/enquiry/sample-request/12508>

Some of the major companies in the global idiopathic thrombocytopenic purpura (ITP) therapeutics market are Hoffman-L Roche, Novartis, GlaxoSmithKline, Eisai, Amgen, GrifolsBiologicals Inc., Baxter, CSL Behring, Bristol-Myers Squibb, and Roxane among others. To enhance their market position in the global idiopathic thrombocytopenic purpura (ITP) therapeutics market, the key players are now focusing on adopting the strategies such as product innovations, mergers & acquisitions, recent developments, joint venture, collaborations, and partnership. For instance, in October 2019, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Nplate (romiplostim) for the treatment of pediatric patients one year of age and older with immune thrombocytopenia (ITP) for at least six months who have not sufficient response to immunoglobulins, corticosteroids, or splenectomy.

The product type segment is divided into corticosteroids, intravenous immunoglobulins, anti-D immunoglobulin, thrombopoietin receptor agonists (TPO-RA), and others. Anti-D

immunoglobulin is expected to grow at the highest CAGR of 6.8% over the forecast period. Anti-D immunoglobulin adoption is rising for the treatment of ITP and now considered as a valid option. The treatment type segment includes splenectomy and oral corticosteroids. The oral corticosteroids segment held the largest market share of 65.2% in 2020. This is mainly due to it is widely used as first-line therapy for the treatment of idiopathic thrombocytopenic purpura (ITP) for both adults and children.

The distribution channel segment includes drug stores, retail pharmacies, and others. The retail pharmacy accounted for the major market share and valued at USD 264.32 million in 2020. This is attributed to the increasing number of trend towards oral therapeutic solutions and procurement of these drugs through retail pharmacies.

[Click Here to Access Full Report Copy](#)

Global idiopathic thrombocytopenic purpura (ITP) therapeutics market is witnessing a considerable growth owing to increasing demand for the combination therapies for the treatment of idiopathic thrombocytopenic purpura (ITP). When first-line therapy fails for effective treatment, alternative therapies are required to treat the disease, including second- and third-line therapies. However, lack of awareness of the disease amongst people and various side effects of corticosteroids, are some of the factors likely to hinder the market growth, over the forecast period.

Customization of the Report:

The customization of this report is available as per the client's need. The report can be customized according to your requirements. We consistently update our research offerings to provide our clients with the latest trends in the market. For customization and to know more about this business report, please contact our sales team at sales@thebrainyinsights.com or +1-315-215-1633. Our sales executives will ensure that you can get a report that fulfills your requirements and suits your needs.

About Us

The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients' objectives of high-quality output within a short span of time. We provide both customized (clients' specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients' requirement whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Mark Stone
The Brainy Insights

+1 315-215-1633

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/554963880>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.